Everolimus-eluting ABSORB bioresorbable vascular scaffold: Present and future perspectives

Expert Review of Medical Devices

Volumn 9, Issue 4, 2012, Pages 327-338

  Brugaletta, Salvatore ^a,b   Garcia Garcia, Hector M ^a   Onuma, Yoshinobu ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

ABSORB; bioresorbable vascular scaffold; everolimus; percutaneous coronary intervention

Indexed keywords

ABSORB; BIORESORBABLE; CLINICAL OUTCOME; CLINICAL STUDY; DRUG-ELUTING STENTS; EVEROLIMUS; FUNCTIONAL MODIFICATION; FUTURE PERSPECTIVES; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED TRIAL; SAFETY CONCERNS; VASCULAR SCAFFOLDS; VASOREACTIVITY;

SCAFFOLDS (BIOLOGY);

SCAFFOLDS;

EVEROLIMUS; POLYLACTIDE;

BIODEGRADABILITY; BIODEGRADABLE IMPLANT; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DEVICE SAFETY; DRUG ELUTING STENT; HUMAN; IMAGE ANALYSIS; INTRAVASCULAR ULTRASOUND; NON INVASIVE MEASUREMENT; NONHUMAN; REVIEW; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; BLOOD VESSELS; DRUG-ELUTING STENTS; HUMANS; POLYESTERS; SIROLIMUS; TISSUE SCAFFOLDS;

EID: 84861226679     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.12.17     Document Type: Review

References (68)

1. de Feyter PJ, de Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am. Heart J. 127(3), 643-651 (1994). (Pubitemid 24124696)
2. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med. 316(12), 701-706 (1987). (Pubitemid 17036474)
3. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: Percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 301(2), 61-68 (1979). (Pubitemid 9229695)
4. Nobuyoshi M, Kimura T, Nosaka H et al. Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angiographic follow-up of 229 patients. J. Am. Coll. Cardiol. 12(3), 616-623 (1988).
5. Gruentzig AR, King SB 3rd, Schlumpf M, Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N. Engl. J. Med. 316(18), 1127-1132 (1987). (Pubitemid 17052502)
6. Serruys PW, Luijten HE, Beatt KJ et al. Incidence of restenosis after successful coronary angioplasty: A time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 77(2), 361-371 (1988). (Pubitemid 18060045)
7. Kimura T, Kaburagi S, Tamura T et al. Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Circulation 96(2), 475-483 (1997). (Pubitemid 27329423)
8. Hoffmann R, Mintz GS, Dussaillant GR et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 94(6), 1247-1254 (1996). (Pubitemid 26307249)
9. Di Mario C, Gil R, Camenzind E et al. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am. J. Cardiol. 75(12), 772-777 (1995).
10. Luo H, Nishioka T, Eigler NL et al. Coronary artery restenosis after balloon angioplasty in humans is associated with circumferential coronary constriction. Arterioscler. Thromb. Vasc. Biol. 16(11), 1393-1398 (1996). (Pubitemid 26378231)
11. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 49(3), 327-333 (1983). (Pubitemid 13012062)
12. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med. 331(8), 489-495 (1994). (Pubitemid 24256751)
13. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. 331(8), 496-501 (1994). (Pubitemid 24256752)
14. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: A nuisance in both bare metal and drug-eluting stents. Circulation 115(11), 1433-1439; discussion 1439 (2007).
15. Costa MA, Sabate M, van der Giessen WJ et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 100(8), 789-792 (1999). (Pubitemid 29398874)
16. Sousa JE, Costa MA, Abizaid AC et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation 104(17), 2007-2011 (2001). (Pubitemid 33027038)
17. Rensing BJ, Vos J, Smits PC et al. Coronary restenosis elimination with a sirolimus eluting stent: First European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur. Heart J. 22(22), 2125-2130 (2001). (Pubitemid 33091454)
18. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346(23), 1773-1780 (2002). (Pubitemid 34586912)
19. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J. Am. Coll. Cardiol. 45(12), 2088-2092 (2005). (Pubitemid 40814135)
20. McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364(9444), 1519-1521 (2004). (Pubitemid 39410418)
21. Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48(12), 2584-2591 (2006). (Pubitemid 44881238)
22. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 369(9562), 667-678 (2007). (Pubitemid 46281313)
23. Wenaweser P, Daemen J, Zwahlen M et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol. 52(14), 1134-1140 (2008).
24. Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46(2), 231-236 (2005). (Pubitemid 40966848)
25. Hofma SH, van der Giessen WJ, van Dalen BM et al. Indication of long-term endothelial dysfunction after sirolimuseluting stent implantation. Eur. Heart J. 27(2), 166-170 (2006). (Pubitemid 43069032)
26. Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial. Lancet 371(9616), 899-907 (2008). (Pubitemid 351384734)
27. Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373(9667), 897-910 (2009).
28. Okamura T, Garg S, Gutierrez-Chico JL et al. In-vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: An OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. Euro Intervention 5(8), 932-938 (2010).
29. Serruys PW, Onuma Y, Dudek D et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis 12-month clinical and imaging outcomes. J. Am. Coll. Cardiol. 58(15), 1578-1588 (2011).
30. Serruys PW, Onuma Y, Ormiston JA et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: Six-month clinical and imaging outcomes. Circulation 122(22), 2301-2312 (2010).
31. Oberhauser JP, Hossainy S, Rapoza R. Design principles and performance of bioresorbable polymeric vascular scaffolds. Euro Intervention 5(Suppl. F), F15-F22 (2009).
32. English J, Perrin D. Polyglycolide and polylactide. In: Handbook of Biodegradable Polymers. Wiseman DM, Kost J, Domb J (Eds). CRC Press, USA (1998).
33. Onuma Y, Serruys PW, Perkins LE et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: An attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 122(22), 2288-2300 (2010).
34. Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 64(1), 36-42 (1997). (Pubitemid 27327197)
35. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiactransplant recipients. N. Engl. J. Med. 349(9), 847-858 (2003). (Pubitemid 37025404)
36. Martinet W, Verheye S, De Meyer GR. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy 3(3), 241-244 (2007). (Pubitemid 46752686)
37. Verheye S, Martinet W, Kockx MM et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J. Am. Coll. Cardiol. 49(6), 706-715 (2007). (Pubitemid 46205042)
38. Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: The ABSORB trial. Euro Intervention 7(9), 1060-1061 (2012).
39. Serruys PW, Ong AT, Piek JJ et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. Euro Intervention 1(1), 58-65 (2005).
40. Serruys PW, Ruygrok P, Neuzner J et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. Euro Intervention 2(3), 286-294 (2006).
41. Bruining N, de Winter S, Roelandt JR et al. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study. JACC Cardiovasc. Interv. 3(4), 449-456 (2010).
42. Garcia-Garcia HM, Gonzalo N, Pawar R et al. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: Temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. Euro Intervention 4(4), 443-448 (2009).
43. Schaar JA, De Korte CL, Mastik F et al. Characterizing vulnerable plaque features with intravascular elastography. Circulation 108(21), 2636-2641 (2003). (Pubitemid 37466804)
44. Schaar JA, Regar E, Mastik F et al. Incidence of high-strain patterns in human coronary arteries: Assessment with three-dimensional intravascular palpography and correlation with clinical presentation. Circulation 109(22), 2716-2719 (2004). (Pubitemid 38737916)
45. Maier W, Windecker S, Kung A et al. Exercise-induced coronary artery vasodilation is not impaired by stent placement. Circulation 105(20), 2373-2377 (2002). (Pubitemid 34556388)
46. Gomez-Lara J, Brugaletta S, Diletti R et al. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur. Heart J. 32(3), 294-304 (2011).
47. Diletti R, Onuma Y, Farooq V et al. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm. J. Am. Coll. Cardiol. 58(3), 258-264 (2011).
48. Brugaletta S, Garcia-Garcia HM, Diletti R et al. Comparison between the first and second generation bioresorbable vascular scaffolds: A six month virtual histology study. Euro Intervention 6(9), 1110-1116 (2011).
49. Brugaletta S, Gomez-Lara J, Serruys PW et al. Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial. JACC Cardiovasc. Interv. 4(12), 1281-1289 (2011).
50. Ormiston JA, De Vroey F, Serruys PW, Webster MW. Bioresorbable polymeric vascular scaffolds: A cautionary tale. Circ. Cardiovasc. Interv. 4(5), 535-538 (2011).
51. Nishio S. Long-term (>10 years) clinical outcomes of first-in-man biodegradable poly-l-lactic acid coronary stents. Presented at: EuroPCR. Paris, France, 25-28 May 2010.
52. Davies G, Hamilton S, Hendrickson E, Levy R, Post F. The effect of cyclandelate in depressed and demented patients: A controlled study in psychogeriatric patients. Age Ageing 6(3), 156-162 (1977). (Pubitemid 8248290)
53. Biamino G, Schmidt A, Scheinert D. Treatment of SFA lesions with PLLA biodegradable stents: Results of the PERSEUS study. J. Endovasc. Ther. 12(Suppl.), 5 (2005).
54. Schulze R. REVA Medical, Inc. Bioresorbable stent. Presented at: Cardiovascular Revascularization Therapies. Washington, DC, USA, 7-9 March 2007.
55. Grube E. Bioabsorbable stent. The Boston Scientific and REVA technology. Presented at: EuroPCR 2009. Barcelona, Spain, 19-22 May 2009.
56. Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K. Novel fully bioabsorbable salicylate-based sirolimuseluting stent. Euro Intervention 5(Suppl. F), F58-F64 (2009).
57. Lafont A, Durand E. A.R.T.: Concept of a bioresorbable stent without drug elution. Euro Intervention 5(Suppl. F), F83-F87 (2009).
58. Erbel R, Di Mario C, Bartunek J et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non-randomised multicentre trial. Lancet 369(9576), 1869-1875 (2007). (Pubitemid 46829357)
59. Barlis P, Tanigawa J, Di Mario C. Coronary bioabsorbable magnesium stent: 15-month intravascular ultrasound and optical coherence tomography findings. Eur. Heart J. 28(19), 2319 (2007). (Pubitemid 47537770)
60. Ghimire G, Spiro J, Kharbanda R et al. Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. Euro Intervention 4(4), 481-484 (2009).
61. Waksman R, Erbel R, Di Mario C et al. Early-and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc. Interv. 2(4), 312-320 (2009).
62. Leimgruber PP, Roubin GS, Hollman J et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 73(4), 710-717 (1986). (Pubitemid 16081430)
63. Nikolsky E, Mehran R, Dangas G et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur. Heart J. 28(16), 1936-1945 (2007). (Pubitemid 47579535)
64. Serruys PW, Morice MC, Kappetein AP et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 360(10), 961-972 (2009).
65. Di Mario C WG, Sianos G, Galassi AR et al. European Perspective in the Recanalization of Chronic Total Occlusions (CTO): Consensus document from the EuroCTO Club. Euro Intervention 3, 30-43 (2007).
66. Spuentrup E, Ruebben A, Mahnken A et al. Artifact-free coronary magnetic resonance angiography and coronary vessel wall imaging in the presence of a new, metallic, coronary magnetic resonance imaging stent. Circulation 111(8), 1019-1026 (2005). (Pubitemid 40354520)
67. Bruining N, Tanimoto S, Otsuka M et al. Quantitative multi-modality imaging analysis of a bioabsorbable poly-l-lactic acid stent design in the acute phase: A comparison between 2-and 3D-QCA, QCU and QMSCTCA. Euro Intervention 4(2), 285-291 (2008).
68. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: Change in paradigm of coronary revascularization in the upcoming decade? Eur. Heart J. 33(1), 16-25 (2011).